Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Ilant Health vs NextMeds

Ilant Health
Graded #407

Lower grade

vs+9.5
NextMeds
Graded #191

Higher grade

The verdict

NextMeds takes it — 66.3/100 to 56.8/100.

NextMeds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NextMeds is a cash-pay telehealth platform offering compounded semaglutide and compounded tirzepatide on a flat monthly membership — one price bundling the medication (if prescribed), telehealth visits, a…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNextMeds +11
45
56
Dose & formulationNextMeds +24
40
64
Clinical oversightIlant Health +6
83
77
Labs & monitoringEven
61
61
FulfillmentNextMeds +22
62
84
Contract termsNextMeds +6
55
61
Ilant Health · left barNextMeds · right bar

The numbers

MetricIlant HealthNextMeds
WeighScore56.8/10066.3/100
GradeCC
Scorecard rank#407#191
SemaglutideNot disclosed$129/mo (plus a separate fee, compounded)
TirzepatideNot disclosed$179/mo (plus a separate fee, compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Ilant Health

Graded #407 · C

Strengths

  • Value-based, outcomes-driven obesity care model
  • Includes GLP-1 medications with transparent drug pricing for sponsors
  • Care team of board-certified obesity providers and behavioral specialists
  • Dietitians and peer navigators support adherence
  • Data-driven stratification targets the right interventions

Where it loses points

  • Distributed via employers and health plans, not direct cash-pay
  • Individuals generally cannot enroll without sponsor coverage
  • No public consumer pricing for GLP-1
  • Access gated behind organizational buyers
  • Not suited to consumers wanting direct-to-door GLP-1
NextMeds

Graded #191 · C

Strengths

  • Flat monthly membership bundles the medication, telehealth visits, a 1:1 care coach and a licensed registered dietitian — one price, no hidden fees
  • Same price every dose, no auto-renewal, cancel anytime; free shipping and no insurance needed (FSA eligible)
  • Names a compounding pharmacy partner (Foothills Pharmacy) and states it services all 50 states
  • Free, no-obligation online assessment before you pay anything

Where it loses points

  • Shows a LegitScript 'approval' but links only a generic directory search, not a verifiable seal — we couldn't independently confirm it
  • Promo-driven pricing with a countdown timer and 'price increases' urgency; the standing membership is $129 (sema) / $179 (tirz)
  • A technology platform that coordinates care, not the medical provider; individual clinicians and a medical director aren't named on the site
  • Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
  • Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard